July 2024
Johnson & Johnson Raises 2024 Guidance Following Acquisition of Shockwave Medical
Johnson & Johnson, Shockwave Medical, 2024 Guidance, Acquisition, Billion-Dollar Potential
Orexo’s Opioid Overdose Nasal Spray Fails FDA Review for Second Time
Orexo, OX124, FDA, Nasal Spray, Opioid Overdose, Naloxone, Human Factors Study, Technical Data
Biopharma Layoff Tracker 2024: Thousands of Jobs Cut Across Industry Giants
Biopharma Layoffs, 2024, Industry Giants, Job Cuts, Restructuring, Cost Savings
Bayer’s NUBEQA Shows Promise in Prostate Cancer Treatment, Expanding Indications
NUBEQA, darolutamide, prostate cancer, metastatic hormone-sensitive prostate cancer, non-metastatic castration-resistant prostate cancer, ARASENS trial, ARAMIS trial, Bayer, Orion Corporation
NGM Bio Secures $122 Million in Funding After Going Private
NGM Bio, funding, private, Column Group, pipeline, orphan diseases
Caribou Biosciences Discontinues CAR-NK Program, Lays Off 21 Employees to Focus on CAR-T Cell Therapies
Caribou Biosciences, CAR-NK, CAR-T, cell therapy, layoffs, biotech, cancer treatment, autoimmune diseases
4DMT’s Wet AMD Gene Therapy Results Disappoint Investors, Stock Plummets
4DMT, Wet AMD, Gene Therapy, Stock Performance, Clinical Trials
VC Firm Oversees NGM Bio’s $122M Series A Funding After Taking it Private
NGM Bio, The Column Group, Venture Capital, Biotech, Series A Funding
Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market
Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures
Elevance Health Surpasses Expectations in Q2 with $2.3 Billion Profit
Elevance Health, Q2 earnings, profit, revenue, Carelon, PBM, insurance premiums